Sopharma AD (BUL:SFA)

Bulgaria · Delayed Price · Currency is BGN

2.780

+0.050 (1.83%)

At close: Dec 5, 2025

46.32% (1Y)

Market Cap	1.44B
Revenue (ttm)	2.51B
Net Income (ttm)	124.18M
Shares Out	519.26M
EPS (ttm)	0.44
PE Ratio	6.28
Forward PE	n/a
Dividend	0.05 (1.89%)
Ex-Dividend Date	Jul 10, 2025

Volume	59,913
Average Volume	45,543
Open	2.730
Previous Close	2.730
Day's Range	2.710 - 2.790
52-Week Range	1.840 - 2.790
Beta	-0.09
RSI	67.20
Earnings Date	Nov 30, 2025

About Sopharma AD

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana to reduce the stress; and medical devices... [Read more]

Industry Pharmaceutical Preparations

Founded 1933

Employees 5,599

Stock Exchange Bulgarian Stock Exchange

Ticker Symbol SFA

Full Company Profile

Financial Performance

In 2024, Sopharma AD's revenue was 2.14 billion, an increase of 13.27% compared to the previous year's 1.89 billion. Earnings were 77.85 million, a decrease of -18.89%.

Financial Statements

News

There is no news available yet.